These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31270078)

  • 1. ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.
    Apsel Winger B; Cortopassi WA; Garrido Ruiz D; Ding L; Jang K; Leyte-Vidal A; Zhang N; Esteve-Puig R; Jacobson MP; Shah NP
    Cancer Res; 2019 Aug; 79(16):4283-4292. PubMed ID: 31270078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.
    Weisberg E; Meng C; Case AE; Sattler M; Tiv HL; Gokhale PC; Buhrlage SJ; Liu X; Yang J; Wang J; Gray N; Stone RM; Adamia S; Dubreuil P; Letard S; Griffin JD
    Br J Haematol; 2019 Nov; 187(4):488-501. PubMed ID: 31309543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors.
    Gebreyohannes YK; Wozniak A; Zhai ME; Wellens J; Cornillie J; Vanleeuw U; Evans E; Gardino AK; Lengauer C; Debiec-Rychter M; Sciot R; Schöffski P
    Clin Cancer Res; 2019 Jan; 25(2):609-618. PubMed ID: 30274985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy.
    Corti C; Conforti F; Pala L; Catania C; Cocorocchio E; Ferrucci PF; Curigliano G; Queirolo P; de Pas T
    Eur J Cancer; 2022 Sep; 172():332-339. PubMed ID: 35820244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avapritinib: First Approval.
    Dhillon S
    Drugs; 2020 Mar; 80(4):433-439. PubMed ID: 32100250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avapritinib for metastatic or unresectable gastrointestinal stromal tumors.
    Alzofon N; Jimeno A
    Drugs Today (Barc); 2020 Sep; 56(9):561-571. PubMed ID: 33025950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanism of D816X mutation-induced c-Kit activation and -mediated inhibitor resistance in gastrointestinal stromal tumor.
    Jiang H; Shao W; Wang Y; Xu R; Zhou L; Mu X
    J Mol Graph Model; 2018 Sep; 84():189-196. PubMed ID: 30015051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis.
    Lübke J; Naumann N; Kluger S; Schwaab J; Metzgeroth G; Evans E; Gardino AK; Lengauer C; Hofmann WK; Fabarius A; Cross NCP; Reiter A; Jawhar M
    Leukemia; 2019 May; 33(5):1195-1205. PubMed ID: 30911112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.
    Carter TA; Wodicka LM; Shah NP; Velasco AM; Fabian MA; Treiber DK; Milanov ZV; Atteridge CE; Biggs WH; Edeen PT; Floyd M; Ford JM; Grotzfeld RM; Herrgard S; Insko DE; Mehta SA; Patel HK; Pao W; Sawyers CL; Varmus H; Zarrinkar PP; Lockhart DJ
    Proc Natl Acad Sci U S A; 2005 Aug; 102(31):11011-6. PubMed ID: 16046538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
    Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
    Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.
    Roskoski R
    Pharmacol Res; 2018 Jul; 133():35-52. PubMed ID: 29704617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of ( E)- N
    Liu X; Wang B; Chen C; Qi Z; Zou F; Wang J; Hu C; Wang A; Ge J; Liu Q; Yu K; Hu Z; Jiang Z; Wang W; Wang L; Wang W; Ren T; Bai M; Liu Q; Liu J
    J Med Chem; 2019 May; 62(10):5006-5024. PubMed ID: 31046271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007-001 Studies.
    Heinrich MC; Zhang X; Jones RL; George S; Serrano C; Deng Y; Bauer S; Cai S; Wu X; Zhou Y; Tao K; Zheng Z; Zhang J; Cui Y; Cao H; Wang M; Hu J; Yang J; Li J; Shen L
    Clin Cancer Res; 2024 Feb; 30(4):719-728. PubMed ID: 38032349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases.
    Klug LR; Kent JD; Heinrich MC
    Pharmacol Ther; 2018 Nov; 191():123-134. PubMed ID: 29964125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
    Debiec-Rychter M; Cools J; Dumez H; Sciot R; Stul M; Mentens N; Vranckx H; Wasag B; Prenen H; Roesel J; Hagemeijer A; Van Oosterom A; Marynen P
    Gastroenterology; 2005 Feb; 128(2):270-9. PubMed ID: 15685537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
    Kayser S; Levis MJ; Schlenk RF
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.
    Smith CC; Zhang C; Lin KC; Lasater EA; Zhang Y; Massi E; Damon LE; Pendleton M; Bashir A; Sebra R; Perl A; Kasarskis A; Shellooe R; Tsang G; Carias H; Powell B; Burton EA; Matusow B; Zhang J; Spevak W; Ibrahim PN; Le MH; Hsu HH; Habets G; West BL; Bollag G; Shah NP
    Cancer Discov; 2015 Jun; 5(6):668-79. PubMed ID: 25847190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A shift of dynamic equilibrium between the KIT active and inactive states causes drug resistance.
    Srikakulam SK; Bastys T; Kalinina OV
    Proteins; 2020 Nov; 88(11):1434-1446. PubMed ID: 32530065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kit Mutations: New Insights and Diagnostic Value.
    Falchi L; Verstovsek S
    Immunol Allergy Clin North Am; 2018 Aug; 38(3):411-428. PubMed ID: 30007460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.